The company
Guardant Health, Inc.
GH · Nasdaq
Health CareDiagnostics & LabsLeading
GH stood above a rising 150-day average in 45 of the last 52 weekly readings, including each of the last 24 weeks. It is 18.8% above that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−6 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 24 in a row
- Industry in uptrend
- 52% +5 in 4 wk
- Insider buys, 12 months
- $157K
- Insider sales, 12 months
- $303.1M
- Officials’ trades on record
- 12
- Institutions holding
- 554 (+100)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 45 of 52 weeks.
23 Apr – 22 Oct
Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
12 disclosed lines: House 11, Senate 1, executive 0; 3 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Jonathan L. Jackson House: U.S. House ClerkIL01 | boughtjoint | $15k–$50k | 28 Sep 2026filed 19 Oct 2026 |
| Sheldon Whitehouse Senate: U.S. Senate eFDSenator | bought | $1k–$15k | 21 Nov 2025filed 1 Dec 2025 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 28 Feb 2022filed 3 Mar 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 13 Jan 2022filed 1 Feb 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 22 Dec 2021filed 1 Jan 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 2 Nov 2020filed 1 Dec 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 22 Oct 2020filed 5 Nov 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 5 Oct 2020filed 5 Nov 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 14 Jul 2020filed 9 Aug 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 1 May 2020filed 31 May 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 27 Apr 2020filed 9 May 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 14 Feb 2020filed 22 Feb 2020 |
Insiders
Buy orders, 12 months1
Sale orders, 12 months58
Buyers · sellers1 · 15
| Who | Did | Shares | Traded |
|---|---|---|---|
| Musa TariqDirector | sold | 116at $165.88 | 16 Oct 2026filed 19 Oct 2026 |
| Alex M. Azar IIDirector | sold | 69at $159.89 | 14 Oct 2026filed 15 Oct 2026 |
| Alex M. Azar IIDirector | sold | 826at $175.00 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 1,103at $174.46 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 3,300at $175.42 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 1,300at $176.34 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 971at $177.48 | 16 Sep 2026filed 17 Sep 2026 |
| Musa TariqDirector | sold | 116at $175.00 | 16 Sep 2026filed 17 Sep 2026 |
| Darya ChudovaChief Technology Officer | sold | 7,738at $178.00 | 15 Sep 2026filed 17 Sep 2026 |
| Kumud KaliaChief Information Officer | sold | 4,000at $158.05 | 11 Sep 2026filed 14 Sep 2026 |
| Amirali TalasazCo-Chief Executive Officer | sold | 9,023at $168.20 | 21 Aug 2026filed 24 Aug 2026 |
| Amirali TalasazCo-Chief Executive Officer | sold | 20,888at $169.16 | 21 Aug 2026filed 24 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders554+100 on the quarter
New · exited148 · 47
Reported value$18.7B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 7,622,935$1.1B | -3,930,824−34.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 5,755,857$863.6M | +131,677+2.3% |
| FMR LLCadded · filed 13 Aug 2026 | 5,488,272$823.4M | +1,372,191+33.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 5,445,785$817.0M | -392,207−6.7% |
| Invesco Ltd.reduced · filed 14 Aug 2026 | 4,429,755$664.6M | -516,714−10.4% |
| GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 2026 | 3,775,895$566.5M | -659,944−14.9% |
| TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026 | 3,719,301$558.0M | -510,230−12.1% |
| Capital International Investorsreduced · filed 12 Aug 2026 | 3,399,604$510.0M | -81,714−2.3% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 3,393,312$509.1M | +55,071+1.6% |
| FRANKLIN RESOURCES INCreduced · filed 13 Aug 2026 | 3,236,065$485.5M | -212,128−6.2% |
31 Mar 2023 – 30 Jun 2026
News
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 - Iberonewsiberonews.com · 20 Oct 2026Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?insidermonkey.com · 20 Oct 2026Guardant Health, Inc.: Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026finanznachrichten.de · 20 Oct 2026Guardant Health Diagnoses Breakout Move | Investor's Business Dailyinvestors.com · 21 Sep 2026Guardant Health, Shield: Teams up with colon cancer coalition's Get Your Rear in Gear® 5K Run/Walk in Milwaukee to increase colorectal cancer screening awareness and educationwisbusiness.com · 18 Sep 2026Guardant Health Nears Buy Point As Sales Outlook Brightensinvestors.com · 16 Sep 2026Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)yahoo.com · 16 Sep 2026Patrick Dempsey Is the New Face of Guardant Health's 'The Reckoning' Campaignadweek.com · 15 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.